Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M3,769Revenue $M85.6Net Margin (%)-30.8Z-Score14.7
Enterprise Value $M3,741EPS $-1.9Operating Margin %-24.7F-Score5
P/E(ttm))0Cash Flow Per Share $-2.0Pre-tax Margin (%)-30.8Higher ROA y-yY
Price/Book25.310-y EBITDA Growth Rate %0Quick Ratio1.5Cash flow > EarningsY
Price/Sales25.45-y EBITDA Growth Rate %-62.0Current Ratio1.6Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-14.8Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-29.2Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M35.7ROI % (ttm)-53.4Gross Margin Increase y-yY

Gurus Latest Trades with PCRX

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PCRXRon Baron 2014-06-30 Add0.05%$63.61 - $91.01
($75.89)
$ 105.539%Add 802.88%154,393
PCRXJoel Greenblatt 2014-06-30 Buy 0.01%$63.61 - $91.01
($75.89)
$ 105.539%New holding, 9486 sh.9,486
PCRXMariko Gordon 2014-06-30 Reduce-0.66%$63.61 - $91.01
($75.89)
$ 105.539%Reduce -17.39%1,132,552
PCRXMariko Gordon 2014-03-31 Add0.19%$55.83 - $80.43
($67.63)
$ 105.556%Add 5.13%1,371,042
PCRXRon Baron 2014-03-31 Add$55.83 - $80.43
($67.63)
$ 105.556%Add 163.28%17,100
PCRXMariko Gordon 2013-12-31 Add2.08%$47.74 - $56.97
($52.53)
$ 105.5101%Add 203.52%1,304,190
PCRXRon Baron 2013-12-31 Buy $47.74 - $56.97
($52.53)
$ 105.5101%New holding, 6495 sh.6,495
PCRXMariko Gordon 2013-09-30 Add0.93%$30.01 - $47.47
($36.37)
$ 105.5190%Add 3812.66%429,688
PCRXMariko Gordon 2013-06-30 Buy 0.02%$25.84 - $30.26
($28.93)
$ 105.5265%New holding, 10982 sh.10,982
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PCRX is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
PCRX Joel Greenblatt 2014-06-309,4860.030.01New Buy
PCRX Ron Baron 2014-06-30154,3930.430.06+802.88%
PCRX Mariko Gordon 2014-06-301,132,5523.184.3-17.39%
Premium Most recent portfolio changes are included for Premium Members only!


PCRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Wicki AndreasDirector 2014-08-29Sell21,494$108.11-2.65view
Wicki AndreasDirector 2014-08-27Sell55,813$108.08-2.62view
Wicki AndreasDirector 2014-08-11Sell150,000$101.253.95view
Scibetta James SSVP, CFO 2014-08-08Sell15,000$99.635.64view
PATOU GARYChief Medical Officer 2014-08-07Sell20,000$100.264.98view
STACK DAVID MPresident, CEO and Chairman 2014-07-15Sell15,000$86.7521.33view
PATOU GARYChief Medical Officer 2014-07-14Sell29,700$86.9621.03view
HASTINGS PAUL JDirector 2014-07-10Sell2,500$84.4124.69view
LONGENECKER JOHN P PHDDirector 2014-06-30Sell1,000$91.614.9view
Wicki AndreasDirector 2014-06-09Sell68,000$85.4323.2view

Press Releases about PCRX :

    Quarterly/Annual Reports about PCRX:

    News about PCRX:

    Articles On GuruFocus.com
    Mariko Gordon's First Quarter Top Five May 15 2014 
    Baron Funds Comments on Pacira Pharmaceuticals Mar 05 2014 
    comment on PCRX Mar 15 2013 
    Weekly CFO Buys Highlight: PCRX, UGI, MIG, GLT, IOSP Feb 27 2011 
    Weekly CFO Buys Highlight: REFR, UGI, PCRX, NOIZ Feb 21 2011 
    Pacira Pharmaceuticals Inc. (PCRX) CFO James S Scibetta buys 5,000 Shares Feb 16 2011 
    Pacira Pharmaceuticals Inc. (PCRX) CEO David M Stack buys 5,000 Shares Feb 11 2011 

    More From Other Websites
    Nasdaq stocks posting largest percentage increases Sep 17 2014
    Tiny Fund That Crushed Market Last Year Is Doing It Again Sep 12 2014
    Aratana Therapeutics Reports Positive Effectiveness Data from Pilot Field Study of Bupivacaine... Sep 09 2014
    There’s good news for speculative growth traders Sep 02 2014
    PACIRA PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Aug 27 2014
    PACIRA PHARMACEUTICALS, INC. Financials Aug 08 2014
    Pacira Pharmaceuticals, Inc. to Present at the Wedbush 2014 Life Sciences Management Access... Aug 05 2014
    Pacira Up on Narrower-than-Expected Loss, Revenue Beat in Q2 Aug 04 2014
    Pacira Pharmaceuticals (PCRX) Hits New Lifetime High Aug 01 2014
    Pacira Pharmaceuticals Inc Earnings Call scheduled for 9:00 am ET today Jul 31 2014
    PACIRA PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 31 2014
    Q2 2014 Pacira Pharmaceuticals, Inc. Earnings Release - Before Market Open Jul 31 2014
    Pacira Pharmaceuticals, Inc. Reports Second Quarter 2014 Results: EXPAREL Revenue up 31% Over First... Jul 31 2014
    UPDATE: Bank Of America Reiterates On Pacira Pharmaceuticals On Positive Survey Results Jul 17 2014
    Pacira Pharmaceuticals Announces Timing for Second Quarter 2014 Financial Results Webcast and... Jul 17 2014
    Pacira's Exparel Positive in Phase IV Studies Jun 27 2014
    Coverage initiated on Pacira Pharma by Canaccord Genuity Jun 27 2014
    Pacira Pharmaceuticals (PCRX) Reaches New Lifetime High Today Jun 19 2014
    UPDATE: JMP Securities Initiates Coverage On Pacira Pharmaceuticals Jun 17 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK